Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Account Payables: 2016-2019

Historic Change in Account Payables for Ultragenyx Pharmaceutical (RARE) over the last 4 years, with Sep 2019 value amounting to $3.9 million.

  • Ultragenyx Pharmaceutical's Change in Account Payables rose 298.58% to $3.9 million in Q3 2019 from the same period last year, while for Sep 2019 it was $4.2 million, marking a year-over-year increase of 517.67%. This contributed to the annual value of $3.4 million for FY2018, which is 2.52% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Change in Account Payables of $3.9 million as of Q3 2019, which was up 211.94% from -$3.5 million recorded in Q2 2019.
  • Ultragenyx Pharmaceutical's Change in Account Payables' 5-year high stood at $4.0 million during Q4 2018, with a 5-year trough of -$3.5 million in Q2 2019.
  • Its 3-year average for Change in Account Payables is $645,182, with a median of -$151,000 in 2019.
  • Within the past 5 years, the most significant YoY rise in Ultragenyx Pharmaceutical's Change in Account Payables was 1,698.93% (2017), while the steepest drop was 343.26% (2017).
  • Over the past 4 years, Ultragenyx Pharmaceutical's Change in Account Payables (Quarterly) stood at -$1.3 million in 2016, then soared by 68.66% to -$420,000 in 2017, then soared by 1,044.05% to $4.0 million in 2018, then surged by 298.58% to $3.9 million in 2019.
  • Its Change in Account Payables was $3.9 million in Q3 2019, compared to -$3.5 million in Q2 2019 and -$151,000 in Q1 2019.